Table 2 Measures reported in the included studies
From: A review of the psychometric performance of the EQ-5D in people with urinary incontinence
Generic measures | Other measures used | |||||
|---|---|---|---|---|---|---|
Author(s), Year | Descriptive system | Tariff used | Direct valuation | Condition-specific HRQoL measures used | Clinical measures used | Qualitative questions |
Ternent et al, 2009 [20] | EQ-5D | Not stated | None | KHQ | None | None |
PGI | ||||||
Ismail et al, 2009 [16] | EQ-5D | Not stated | None | KHQ | 1 hr pad test | None |
Leakage episodes | ||||||
Pad usage | ||||||
Rinne et al, 2008 [22] | EQ-5D | Not stated | None | UISS | Cough stress test | Satisfaction with operation. |
DIS | 24-hr pad | |||||
VAS | ||||||
IIQ-7 | ||||||
UDI-6 | ||||||
Haywood et al, 2008 [7] | EQ-5D | States general population utility weights. | None | I-QoL (index and individual domains) | SSI | Subjective treatment benefit assessed by patient. |
Incontinence episodes per week at baseline | ||||||
Monz et al, 2007 [12] | EQ-5D | Not stated | EQ-VAS | I-QOL | UI severity (Sandvik Index) | Bother (4 point scale) |
UI subtype (S/UIQ) | ||||||
Kobelt et al, 2006 [21] | EQ-5D | Reference suggests UK tariff used. | None | None | Incontinence grade | |
Median number of episodes per day | ||||||
Dumville et al, 2006 [17] | EQ-5D | UK tariff | None | None | Objective cure* (negative 1 hr pad test) | Subjective cure* (perfectly happy / pleased) to spend rest of life with current urinary symptoms |
SF-36 | ||||||
*(reported in related clinical paper) | ||||||
Currie et al, 2006 [10] | EQ-5D | Not stated | None | None | None | None |
SF-36 | ||||||
Monz et al, 2005 [13] | EQ-5D | Not stated | None | I-QOL | Sandvik index (severity based on frequency and leakage amount) | Bothersomeness and limitations of daily activities |
Manca et al, 2003 [18] | EQ-5D | UK tariff | Objective cure (based on negative pad test and negative cystometry) | |||
SF-36 | ||||||
Subjective cure (based on BFLUTS) | ||||||
Kobelt, 1997 [14] | EQ-5D | UK tariff. | EQ-VAS [15] | Frequency of micturitions and involuntary urine loss (combined measure) | ||
SF-36 | ||||||
Hawthorn, 2009 [2] | EQ-5D | EQ-5D: UK tariff | ||||
SF-6D | ||||||
AQoL | SF-6D: Not stated | |||||
AQoL-8 (derived from | ||||||
AQoL & | ||||||
AQoL) | AQoL-8: community TTO | |||||
HUI-3 (deciles) | ||||||
Tincello et al, 2010 [19] | EQ-5D | UK tariff | None | None | Episodes per week | None |
Saarni, 2006 [9] | EQ-5D | EQ-5D: UK tariff | None | None | None | |
15-D | ||||||
15-D Finnish valuation set | ||||||
Noble et al, 2002 [11] | EQ-5D | Not stated | None | I-PSS which includes a quality of life score. | Maximum flow rate | |
Post void residual urine | ||||||
Number of successful procedures (based on I-PSS and maximum urinary flow) | ||||||
Mihaylova et al, 2010 [23] | EQ-5D | UK tariff | Number of leaks during 7 days | |||
Donovan et al, 1997 [8] | EQ-5D (UK, Denmark and Netherland only, N=359) | Not reported | ICSQol (ICSmale) | |||
SF-36 (UK only, N=205) | ||||||